Yükleniyor... / Loading...
This study assesses the late effects of curative therapies for sickle cell disease. It enrolls patients with a laboratory-confirmed diagnosis of sickle cell disease who have been treated with either a stem cell transplant (HSCT) or standard disease-modifying therapy and can provide pre- and post-treatment data. It is conducted as a study without a phase designation and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria * Confirmed laboratory diagnosis of SCD * Ability to give informed consent * Ability to provide pre- and post-curative therapy data * Treated with either one HSCT or with standard disease-modifying therapy Exclusion Criteria •History of non-compliance